Insulin powerhouse Novo Nordisk will discontinue its long-acting insulin Levemir in the US next year amid anticipated supply disruptions, a 65% price cut and as the company faces price negotiations with CMS for its other insulins.
The Danish drugmaker said supply disruptions of Levemir FlexPen are…
Click here to view original post
